Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

Status Recruiting

Clinical Trial Summary

Food allergy (FA) is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children, 30% with multiple food allergies) and about 9% of adults. This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be a peanut. The total of participants in the clinical study will be 110, ages 4 to 55 years with a history of multiple food allergies of 2 to 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the Double-blind Placebo-controlled Food challenge (DBPCFC) at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.

Clinical Trial Description

This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be peanut. The total population will be 110 participants, ages 4 to 55 years that present with a history of multiple food allergies of 2 or 3 different foods including peanut, food-allergen (FA)-specific IgE levels, and positive skin prick test (SPT). Enrolled participants must react positively during DBPCFCs at or before the 300 mg (444 mg cumulative) dosing level of FA proteins of 2 or 3 allergens in which one must be a peanut. There will be three study cohorts, all will be double blinded: Cohort A (50 participants) will be treated with omalizumab for 8 weeks followed by 24 weeks of treatment with placebo. Cohort B (50 participants) will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab. Cohort C (10 participants) will be treated with placebo for 8 weeks followed by 24 weeks treatment with dupilumab. All cohorts will receive multifood allergen oral immunotherapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03679676
Study type	Interventional
Source	Stanford University
Contact	SNP Center Inquiry
Phone	650-521-7237
Email	snpcenterallergy_inquiry@stanford.edu
Status	Recruiting
Phase	Phase 2
Start date	February 5, 2020
Completion date	September 2025

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03089476` - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy	N/A
Recruiting	`NCT05839405` - Food Allergy in the Brain
Completed	`NCT02552537` - iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions	Phase 4
Completed	`NCT01634737` - Crustacean Allergy and Dust Mites Sensitization	N/A
Recruiting	`NCT05521711` - TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation	N/A
Completed	`NCT05072665` - Fast Allergy Sensitivity Test	N/A
Active, not recruiting	`NCT04887441` - Allergology: Information, Data and Knowledge Organization
Recruiting	`NCT03265262` - The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy	N/A
Completed	`NCT04186949` - Early Origins of Allergy and Asthma
Completed	`NCT02490007` - Pertussis Immunisation and Food Allergy
Recruiting	`NCT03151252` - Improvement of Foodallergy Diagnostic in Gastrointestinal Tract	N/A
Completed	`NCT02159833` - Intranasal Diagnostics in Food Allergy: a Feasibility Study	N/A
Completed	`NCT02377284` - Prevention and Management of Food Allergies	N/A
Completed	`NCT02354729` - Encouraging Allergic Young Adults to Carry Epinephrine	N/A
Completed	`NCT02640560` - One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish	N/A
Enrolling by invitation	`NCT06097572` - Improved Diagnostics in Food Allergy Study	N/A
Recruiting	`NCT04606615` - Skin Barrier Abnormalities and Oxidative Stress Response
Recruiting	`NCT05785299` - Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy	N/A
Not yet recruiting	`NCT06112873` - Quality of Life in Food Allergy: Validation of Three Mini-questionnaires
Completed	`NCT03337802` - Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.